Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials
Value in Health · 2023
DOI: 10.1016/j.jval.2023.06.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2023. Verfasst von Bellinda L King-Kallimanis und 14 weiteren Autor:innen. Beteiligte Einrichtung: LUNGevity Foundation, Bethesda, MD, USA. Electronic address: bking-kallimanis@lungevity.org. Hauptthemen laut MEDLINE: Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Patient-reported outcome (PRO) data are critical in understanding treatments from the patient perspective in cancer clinical trials. The potential benefits and methodological approaches to the collection of PRO data after treatment discontinuation (eg, because of progressive disease or unacceptable drug toxicity) are less clear. The purpose of this article is to describe the Food and Drug Administration's Oncology Center of Excellence and the Critical Path Institute cosponsored 2-hour virtual roundtable, held in 2020, to discuss this specific issue. METHODS: We summarize key points from this discussion with 16 stakeholders representing academia, clinical practice, patients, international regulatory agencies, health technology assessment bodies/payers, industry, and PRO instrument development. RESULTS: Stakeholders recognized that any PRO data collection after treatment discontinuation should have clearly defined objectives to ensure that data can be analyzed and reported. CONCLUSIONS: Data collection after discontinuation without a justification for its use wastes patients' time and effort and is unethical.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- LUNGevity Foundation, Bethesda, MD, USA. Electronic address: bking-kallimanis@lungevity.org.
- Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, England, UK; Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, College of…
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
- Adelphi Values, Cheshire, England, UK.
- Quality of Life Department, EORTC HQ, Brussels, Belgium.
- Colorado School of Public Health, Aurora, CO, USA.
Zitieren
APA
King-Kallimanis, B. L., Calvert, M., Cella, D., Cocks, K., Coens, C., Fairclough, D., Howie, L., Jonsson, P., Mahendraratnam, N., Maues, J., Sarac, S., Shaw, J., Stigger, N., Trask, P., & Wieseler, B. (2023). Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials. Value in Health. https://doi.org/10.1016/j.jval.2023.06.019
Vancouver
King-Kallimanis BL, Calvert M, Cella D, Cocks K, Coens C, Fairclough D, et al. Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials. Value in Health. 2023. doi:10.1016/j.jval.2023.06.019
BibTeX
@article{KingKallimanis2023,
author = {King-Kallimanis, Bellinda L and Calvert, Melanie and Cella, David and Cocks, Kim and Coens, Corneel and Fairclough, Diane and Howie, Lynn and Jonsson, Pall and Mahendraratnam, Nirosha and Maues, Julia and Sarac, Sinan and Shaw, Jim and Stigger, Nichelle and Trask, Peter and Wieseler, Beate},
title = {Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials},
journal = {Value in Health},
year = {2023},
doi = {10.1016/j.jval.2023.06.019}
}
EUVIMED